Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Audentes Therapeutics, Inc. (BOLD) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Audentes Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1628738.
Total stock buying since 2016: $11,600,008.
Total stock sales since 2016: $61,039,213.
Total stock option exercises since 2016: $5,737,508.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2020 | 0 | $0 | 0 | $0 | 313,426 | $2,486,515 |
| 2019 | 0 | $0 | 139,984 | $5,023,619 | 272,391 | $2,858,570 |
| 2018 | 0 | $0 | 931,173 | $32,673,865 | 239,722 | $248,799 |
| 2017 | 172,413 | $2,499,988 | 840,600 | $23,341,729 | 83,500 | $143,624 |
| 2016 | 606,668 | $9,100,020 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2020-01 | 0 | $0 | 0 | $0 | 313,426 | $2,486,515 |
| 2019-12 | 0 | $0 | 11,000 | $655,578 | 188,665 | $2,461,589 |
| 2019-11 | 0 | $0 | 14,426 | $432,780 | 14,426 | $137,047 |
| 2019-09 | 0 | $0 | 11,000 | $355,641 | 0 | $0 |
| 2019-08 | 0 | $0 | 20,000 | $685,420 | 20,000 | $190,000 |
| 2019-06 | 0 | $0 | 21,000 | $810,978 | 0 | $0 |
| 2019-05 | 0 | $0 | 10,000 | $373,480 | 10,000 | $7,900 |
| 2019-03 | 0 | $0 | 21,558 | $779,192 | 0 | $0 |
| 2019-02 | 0 | $0 | 31,000 | $930,550 | 31,000 | $39,085 |
| 2019-01 | 0 | $0 | 0 | $0 | 8,300 | $22,949 |
| 2018-12 | 0 | $0 | 32,000 | $596,640 | 40,000 | $31,200 |
| 2018-11 | 0 | $0 | 24,000 | $539,760 | 0 | $0 |
| 2018-10 | 0 | $0 | 31,000 | $1,181,843 | 31,000 | $24,280 |
| 2018-09 | 0 | $0 | 46,039 | $1,755,430 | 28,039 | $40,155 |
| 2018-07 | 0 | $0 | 81,048 | $3,198,011 | 81,048 | $63,316 |
| 2018-06 | 0 | $0 | 46,545 | $1,932,298 | 18,635 | $43,668 |
| 2018-05 | 0 | $0 | 20,300 | $775,257 | 20,300 | $15,834 |
| 2018-04 | 0 | $0 | 700 | $21,009 | 700 | $546 |
| 2018-03 | 0 | $0 | 649,541 | $22,673,617 | 20,000 | $29,800 |
| 2017-12 | 0 | $0 | 26,000 | $785,548 | 8,000 | $6,320 |
| 2017-11 | 0 | $0 | 10,000 | $268,990 | 10,000 | $21,900 |
| 2017-10 | 0 | $0 | 25,000 | $698,075 | 10,000 | $7,800 |
| 2017-09 | 0 | $0 | 731,500 | $20,551,505 | 25,500 | $30,505 |
| 2017-08 | 0 | $0 | 10,000 | $200,000 | 10,000 | $21,900 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-01-08 | Soloway Thomas P (Executive Vice President, CFO) | Option Ex | 150,888 | 9.01 | 1,359,802 |
| 2020-01-08 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 162,538 | 6.93 | 1,126,713 |
| 2019-12-23 | Lange Louis G (Director) | Sale | 11,000 | 59.60 | 655,578 |
| 2019-12-12 | Holles Natalie C. (President and COO) | Option Ex | 147,344 | 15.93 | 2,347,337 |
| 2019-12-12 | Soloway Thomas P (Executive Vice President, CFO) | Option Ex | 41,321 | 2.77 | 114,252 |
| 2019-11-08 | Patterson Matthew R (Chief Executive Officer) | Sale | 14,426 | 30.00 | 432,780 |
| 2019-11-08 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 14,426 | 9.50 | 137,047 |
| 2019-09-23 | Lange Louis G (Director) | Sale | 11,000 | 32.33 | 355,641 |
| 2019-08-12 | Patterson Matthew R (Chief Executive Officer) | Sale | 20,000 | 34.27 | 685,420 |
| 2019-08-12 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 20,000 | 9.50 | 190,000 |
| 2019-06-24 | Lange Louis G (Director) | Sale | 21,000 | 38.62 | 810,978 |
| 2019-05-13 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 10,000 | 37.35 | 373,480 |
| 2019-05-13 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 10,000 | .79 | 7,900 |
| 2019-03-25 | Lange Louis G (Director) | Sale | 21,558 | 36.14 | 779,192 |
| 2019-02-25 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 10,000 | 30.05 | 300,550 |
| 2019-02-25 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 10,000 | .79 | 7,900 |
| 2019-02-25 | Patterson Matthew R (Chief Executive Officer) | Sale | 21,000 | 30.00 | 630,000 |
| 2019-02-25 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 21,000 | 1.49 | 31,185 |
| 2019-01-24 | Holles Natalie C. (President and COO) | Option Ex | 8,300 | 2.77 | 22,949 |
| 2018-12-24 | Lange Louis G (Director) | Sale | 32,000 | 18.64 | 596,640 |
| 2018-12-06 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 40,000 | .78 | 31,200 |
| 2018-11-15 | Lange Louis G (Director) | Sale | 24,000 | 22.49 | 539,760 |
| 2018-10-01 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 10,000 | 37.62 | 376,220 |
| 2018-10-01 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 10,000 | .79 | 7,900 |
| 2018-10-01 | Patterson Matthew R (Chief Executive Officer) | Sale | 21,000 | 38.36 | 805,623 |
| 2018-10-01 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 21,000 | .78 | 16,380 |
| 2018-09-28 | Gray John T. (SVP, Chief Scientific Officer) | Sale | 87 | 40.00 | 3,480 |
| 2018-09-28 | Gray John T. (SVP, Chief Scientific Officer) | Option Ex | 87 | 1.05 | 91 |
| 2018-09-24 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 15,000 | .78 | 11,700 |
| 2018-09-24 | Lange Louis G (Director) | Sale | 33,000 | 37.39 | 1,233,870 |
| 2018-09-18 | Patterson Matthew R (Chief Executive Officer) | Sale | 12,952 | 40.00 | 518,080 |
| 2018-09-18 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 12,952 | 2.19 | 28,364 |
| 2018-07-05 | Patterson Matthew R (Chief Executive Officer) | Sale | 23,147 | 40.04 | 926,852 |
| 2018-07-05 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 23,147 | .78 | 18,054 |
| 2018-07-03 | Patterson Matthew R (Chief Executive Officer) | Sale | 26,901 | 40.05 | 1,077,465 |
| 2018-07-03 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 26,901 | .78 | 20,982 |
| 2018-07-02 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 10,000 | 38.41 | 384,060 |
| 2018-07-02 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 10,000 | .79 | 7,900 |
| 2018-07-02 | Patterson Matthew R (Chief Executive Officer) | Sale | 21,000 | 38.55 | 809,634 |
| 2018-07-02 | Patterson Matthew R (Chief Executive Officer) | Option Ex | 21,000 | .78 | 16,380 |
| 2018-06-25 | Newman Mary (SVP, Regulatory Affairs) | Sale | 8,545 | 41.07 | 350,968 |
| 2018-06-25 | Newman Mary (SVP, Regulatory Affairs) | Option Ex | 8,545 | 2.19 | 18,670 |
| 2018-06-25 | Lange Louis G (Director) | Sale | 33,000 | 41.01 | 1,353,165 |
| 2018-06-20 | Nagler David (SVP, HR & Corp. Affairs) | Sale | 5,000 | 45.63 | 228,165 |
| 2018-06-20 | Nagler David (SVP, HR & Corp. Affairs) | Option Ex | 5,000 | 2.19 | 10,925 |
| 2018-06-01 | Holles Natalie C. (President and COO) | Option Ex | 5,090 | 2.77 | 14,073 |
| 2018-05-21 | Patterson Matthew R (President & CEO) | Sale | 20,300 | 38.19 | 775,257 |
| 2018-05-21 | Patterson Matthew R (President & CEO) | Option Ex | 20,300 | .78 | 15,834 |
| 2018-04-02 | Patterson Matthew R (President & CEO) | Sale | 700 | 30.01 | 21,009 |
| 2018-04-02 | Patterson Matthew R (President & CEO) | Option Ex | 700 | .78 | 546 |
| 2018-03-29 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 7,800 | .79 | 6,162 |
| 2018-03-27 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 300 | .79 | 237 |
| 2018-03-26 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 1,900 | 30.00 | 57,000 |
| 2018-03-26 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 1,900 | .79 | 1,501 |
| 2018-03-26 | Lange Louis G (Director) | Sale | 48,000 | 29.07 | 1,395,168 |
| 2018-03-15 | Newman Mary (SVP, Regulatory Affairs) | Sale | 10,000 | 30.69 | 306,890 |
| 2018-03-15 | Newman Mary (SVP, Regulatory Affairs) | Option Ex | 10,000 | 2.19 | 21,900 |
| 2018-03-12 | Orbimed Capital Gp Iv Llc | Sale | 18,003 | 35.48 | 638,746 |
| 2018-03-09 | Orbimed Capital Gp Iv Llc | Sale | 80,000 | 35.66 | 2,852,559 |
| 2018-03-08 | Orbimed Capital Gp Iv Llc | Sale | 58,428 | 34.06 | 1,990,057 |
| 2018-03-06 | Orbimed Capital Gp Iv Llc | Sale | 11,372 | 33.03 | 375,617 |
| 2018-03-05 | Orbimed Capital Gp Iv Llc | Sale | 200 | 36.06 | 7,212 |
| 2018-03-02 | Orbimed Capital Gp Iv Llc | Sale | 421,638 | 35.70 | 15,050,368 |
| 2017-12-22 | Lange Louis G (Director) | Sale | 18,000 | 30.88 | 555,804 |
| 2017-12-01 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 8,000 | 28.72 | 229,744 |
| 2017-12-01 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 8,000 | .79 | 6,320 |
| 2017-11-16 | Newman Mary (SVP, Regulatory Affairs) | Sale | 10,000 | 26.90 | 268,990 |
| 2017-11-16 | Newman Mary (SVP, Regulatory Affairs) | Option Ex | 10,000 | 2.19 | 21,900 |
| 2017-10-02 | Patterson Matthew R (President & CEO) | Sale | 25,000 | 27.92 | 698,075 |
| 2017-10-02 | Patterson Matthew R (President & CEO) | Option Ex | 10,000 | .78 | 7,800 |
| 2017-09-29 | Lange Louis G (Director) | Sale | 11,000 | 28.72 | 315,942 |
| 2017-09-29 | Isaly Samuel D | Sale | 672,000 | 28.25 | 18,984,000 |
| 2017-09-27 | Nagler David (SVP, HR & Corp. Affairs) | Sale | 3,750 | 30.00 | 112,500 |
| 2017-09-27 | Nagler David (SVP, HR & Corp. Affairs) | Option Ex | 3,750 | 2.19 | 8,193 |
| 2017-09-25 | Lange Louis G (Director) | Sale | 18,000 | 28.42 | 511,524 |
| 2017-09-18 | Patterson Matthew R (President & CEO) | Sale | 8,458 | 25.07 | 212,008 |
| 2017-09-18 | Patterson Matthew R (President & CEO) | Option Ex | 8,458 | .78 | 6,597 |
| 2017-09-15 | Nagler David (SVP, HR & Corp. Affairs) | Sale | 3,750 | 25.00 | 93,750 |
| 2017-09-15 | Nagler David (SVP, HR & Corp. Affairs) | Option Ex | 3,750 | 2.19 | 8,193 |
| 2017-09-15 | Patterson Matthew R (President & CEO) | Sale | 1,542 | 25.00 | 38,551 |
| 2017-09-15 | Patterson Matthew R (President & CEO) | Option Ex | 1,542 | .78 | 1,202 |
| 2017-09-07 | Isaly Samuel D | Sale | 5,000 | 22.35 | 111,750 |
| 2017-09-01 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 8,000 | 21.43 | 171,480 |
| 2017-09-01 | Prasad Suyash (Senior VP & Chief Med Officer) | Option Ex | 8,000 | .79 | 6,320 |
| 2017-08-24 | Newman Mary (SVP, Regulatory Affairs) | Sale | 10,000 | 20.00 | 200,000 |
| 2017-08-24 | Newman Mary (SVP, Regulatory Affairs) | Option Ex | 10,000 | 2.19 | 21,900 |
| 2017-07-13 | Patterson Matthew R (President & CEO) | Sale | 12,150 | 20.00 | 243,048 |
| 2017-07-12 | Patterson Matthew R (President & CEO) | Sale | 2,850 | 20.00 | 57,008 |
| 2017-06-26 | Lange Louis G (Director) | Sale | 15,000 | 19.62 | 294,360 |
| 2017-05-31 | Holles Natalie C. (Senior Vice President, COO) | Option Ex | 20,000 | 2.76 | 55,199 |
| 2017-04-24 | Rocklage Scott M (Other) | Buy | 172,413 | 14.50 | 2,499,988 |
| 2017-03-29 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 7,800 | 30.02 | 234,195 |
| 2017-03-27 | Prasad Suyash (Senior VP & Chief Med Officer) | Sale | 300 | 30.00 | 9,000 |
| 2016-07-25 | Woiwode Thomas (Director) | Buy | 35,000 | 15.00 | 525,000 |
| 2016-07-25 | Deerfield Private Design Fund Iii, L.p. | Buy | 400,000 | 15.00 | 6,000,000 |
| 2016-07-25 | 5am Partners Iii, Llc (10% Owner) | Buy | 70,000 | 15.00 | 1,050,000 |
| 2016-07-25 | Versant Ventures Iv, Llc (10% Owner) | Buy | 35,000 | 15.00 | 525,000 |
| 2016-07-25 | Silverstein Jonathan (Director) | Buy | 33,334 | 15.00 | 500,010 |
| 2016-07-25 | Orbimed Advisors Llc (Director) | Buy | 33,334 | 15.00 | 500,010 |
Insider trading activities including stock purchases, stock sales, and option exercises of BOLD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Audentes Therapeutics, Inc. (symbol BOLD, CIK number 1628738) see the Securities and Exchange Commission (SEC) website.